The net proceeds received by the Company hereunder shall be used to manufacture drugs, finish the Phase 1 trial, manufacture for the Phase 2a trial, IP costs, sponsored research at MD Anderson and general corporate purposes. The Company may not use funds received by the Company at any time to lend money, give credit or make advances to any officers, directors, employees, related parties, shareholders or affiliates of the Company.